We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Globus Medical (GMED) Down 9.2% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Globus Medical (GMED - Free Report) . Shares have lost about 9.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Globus Medical due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Globus Medical, Inc. before we dive into how investors and analysts have reacted as of late.
GMED Q4 Earnings and Revenues Beat Estimates
Globus Medical (GMED - Free Report) reported fourth-quarter adjusted earnings per share (EPS) of $1.28 per share, up 52.1% year over year. The figure surpassed the Zacks Consensus Estimate by 20.8%.
Adjusted EPS excludes certain non-recurring expenses and benefits, such as the amortization of intangibles, merger and acquisition-related costs/licensing and the provision for litigation.
Without adjustments, the company registered a GAAP diluted EPS of $1.03 compared with 19 cents in the year-ago period.
Full-year 2025 adjusted EPS of $3.98 rose 30.8% year over year. The figure surpassed the Zacks Consensus Estimate by 4.7%.
GMED’s Revenues
Fourth-quarter worldwide sales increased 25.7% year over year to $826.4 million. The reported figure beat the Zacks Consensus Estimate by 4.9%.
Full-year 2025 worldwide sales increased 16.7% year over year to $2.94 billion. The reported figure beat the Zacks Consensus Estimate by 1.7%.
GMED’s 2026 Guidance
Globus Medical reaffirms its guidance for full-year revenues at $3.18-$3.22 billion. The Zacks Consensus Estimate is currently pegged at $3.15 billion.
The company updated its guidance for non-GAAP fully diluted EPS to $4.40-$4.50 (up from $4.30-$4.40). The Zacks Consensus Estimate is pegged at $3.89.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted 7.35% due to these changes.
VGM Scores
Currently, Globus Medical has a nice Growth Score of B, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Globus Medical has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Globus Medical (GMED) Down 9.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Globus Medical (GMED - Free Report) . Shares have lost about 9.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Globus Medical due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Globus Medical, Inc. before we dive into how investors and analysts have reacted as of late.
GMED Q4 Earnings and Revenues Beat Estimates
Globus Medical (GMED - Free Report) reported fourth-quarter adjusted earnings per share (EPS) of $1.28 per share, up 52.1% year over year. The figure surpassed the Zacks Consensus Estimate by 20.8%.
Adjusted EPS excludes certain non-recurring expenses and benefits, such as the amortization of intangibles, merger and acquisition-related costs/licensing and the provision for litigation.
Without adjustments, the company registered a GAAP diluted EPS of $1.03 compared with 19 cents in the year-ago period.
Full-year 2025 adjusted EPS of $3.98 rose 30.8% year over year. The figure surpassed the Zacks Consensus Estimate by 4.7%.
GMED’s Revenues
Fourth-quarter worldwide sales increased 25.7% year over year to $826.4 million. The reported figure beat the Zacks Consensus Estimate by 4.9%.
Full-year 2025 worldwide sales increased 16.7% year over year to $2.94 billion. The reported figure beat the Zacks Consensus Estimate by 1.7%.
GMED’s 2026 Guidance
Globus Medical reaffirms its guidance for full-year revenues at $3.18-$3.22 billion. The Zacks Consensus Estimate is currently pegged at $3.15 billion.
The company updated its guidance for non-GAAP fully diluted EPS to $4.40-$4.50 (up from $4.30-$4.40). The Zacks Consensus Estimate is pegged at $3.89.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted 7.35% due to these changes.
VGM Scores
Currently, Globus Medical has a nice Growth Score of B, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Globus Medical has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.